# Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

> **NCT01532960** · PHASE1 · TERMINATED · sponsor: **Craig L Slingluff, Jr** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** poly-ICLC
- **BIOLOGICAL:** 9 Peptides from Her-2/neu, CEA, & CTA
- **BIOLOGICAL:** Peptide-tet

## Key facts

- **NCT ID:** NCT01532960
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Futility for immune responses to the vaccine. Also, a component of study drug was in short supply.
- **Last updated:** 2020-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532960, "Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01532960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*